Summary:
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Qualified Participants Must:
Adults aged 40 years and older, with COPD and with chronic bronchitis
Current smokers or ex-smokers (history of 10 pack years or higher)
Post-bronchodilator FEV1 less than 50% of the patient predicted normal value and FEV1/FVC ratio less than 0.7
At least, one moderate or severe COPD exacerbation in the previous year
CAT score greater than 10
Subjects on regular maintenance triple therapy for at least 12 months
Qualified Participants May Receive:
May receive reimbursement for time and travel for study participation, if you qualify.